Free Trial

Nuvectis Pharma (NVCT) Competitors

Nuvectis Pharma logo
$7.77 +0.04 (+0.53%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NVCT vs. DAWN, ATAI, AUTL, XNCR, ABVX, TLRY, MRVI, PRME, RLAY, and ABUS

Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), Autolus Therapeutics (AUTL), Xencor (XNCR), Abivax (ABVX), Tilray Brands (TLRY), Maravai LifeSciences (MRVI), Prime Medicine (PRME), Relay Therapeutics (RLAY), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

Nuvectis Pharma vs. Its Competitors

Day One Biopharmaceuticals (NASDAQ:DAWN) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Nuvectis Pharma has lower revenue, but higher earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Day One Biopharmaceuticals$131.16M5.59-$95.50M-$0.71-10.19
Nuvectis PharmaN/AN/A-$19M-$1.13-6.88

88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 6.2% of Day One Biopharmaceuticals shares are owned by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuvectis Pharma has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -42.66%. Day One Biopharmaceuticals' return on equity of -14.98% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Day One Biopharmaceuticals-42.66% -14.98% -13.04%
Nuvectis Pharma N/A -148.83%-95.60%

Day One Biopharmaceuticals has a beta of -1.27, suggesting that its share price is 227% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.

In the previous week, Day One Biopharmaceuticals had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 4 mentions for Day One Biopharmaceuticals and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.93 beat Day One Biopharmaceuticals' score of 0.89 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Day One Biopharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuvectis Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Day One Biopharmaceuticals presently has a consensus target price of $29.00, indicating a potential upside of 300.83%. Nuvectis Pharma has a consensus target price of $17.00, indicating a potential upside of 118.76%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Day One Biopharmaceuticals is more favorable than Nuvectis Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Day One Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Nuvectis Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Day One Biopharmaceuticals beats Nuvectis Pharma on 9 of the 16 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVCT vs. The Competition

MetricNuvectis PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$162.11M$3.04B$5.72B$9.52B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-6.8721.1228.0720.02
Price / SalesN/A340.60462.58104.32
Price / CashN/A43.2336.5558.97
Price / Book15.548.338.645.90
Net Income-$19M-$55.19M$3.24B$258.50M
7 Day Performance-0.37%5.91%4.08%2.12%
1 Month Performance0.40%17.69%10.68%12.62%
1 Year Performance17.39%5.36%34.47%19.25%

Nuvectis Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVCT
Nuvectis Pharma
2.7237 of 5 stars
$7.77
+0.5%
$17.00
+118.8%
+11.2%$162.11MN/A-6.878
DAWN
Day One Biopharmaceuticals
2.7169 of 5 stars
$6.40
flat
$29.00
+353.1%
-53.2%$648.72M$131.16M-9.0160News Coverage
ATAI
atai Life Sciences
3.437 of 5 stars
$3.53
+9.3%
$9.00
+155.0%
+147.7%$647.09M$310K-3.8880Gap Up
High Trading Volume
AUTL
Autolus Therapeutics
2.6099 of 5 stars
$2.43
+0.8%
$9.32
+283.5%
-38.5%$641.40M$10.12M-2.76330Gap Up
XNCR
Xencor
4.5069 of 5 stars
$9.10
+1.4%
$28.00
+207.7%
-54.7%$638.40M$110.49M-2.97280
ABVX
Abivax
2.4006 of 5 stars
$10.14
+1.9%
$31.00
+205.7%
+488.7%$631.55MN/A0.0061Trending News
Analyst Forecast
Analyst Revision
Gap Down
High Trading Volume
TLRY
Tilray Brands
1.8236 of 5 stars
$0.67
+8.4%
$1.92
+184.6%
-60.7%$625.34M$210.48M-0.642,650Upcoming Earnings
Options Volume
MRVI
Maravai LifeSciences
3.6062 of 5 stars
$2.38
-2.1%
$6.64
+178.9%
-67.3%$618.82M$259.18M-2.09610Options Volume
PRME
Prime Medicine
3.853 of 5 stars
$4.57
+10.7%
$9.25
+102.4%
-20.8%$614.65M$3.85M-2.23234Gap Down
High Trading Volume
RLAY
Relay Therapeutics
2.6502 of 5 stars
$3.63
+3.7%
$17.67
+386.7%
-58.8%$600.06M$10.01M-1.63330News Coverage
ABUS
Arbutus Biopharma
2.2729 of 5 stars
$3.14
+0.3%
$5.50
+75.2%
-16.3%$599.48M$6.17M-7.6690

Related Companies and Tools


This page (NASDAQ:NVCT) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners